39698-78-7
Chemical Structure
Saralasin acetate hydrate
Synonym(s): [Sar1,Ala8] Angiotensin II acetate hydrate
- CAS No.: 39698-78-7
- Formula:C44H71N13O13
- Molecular Weight:N/A
SMILES: CC(O)=O.O=C([C@H](CC1=CNC=N1)NC([C@@H](NC([C@H](CC2=CC=C(C=C2)O)NC([C@@H](NC([C@@H](NC(CNC)=O)CCCNC(N)=N)=O)C(C)C)=O)=O)C(C)C)=O)N3CCC[C@H]3C(N[C@H](C(O)=O)C)=O.[H]O[H].[x].[x]
Biological Activity: Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension[1][3][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Saralasin acetate hydrate | Saralasin ([Sar1,Ala8] Angiotensin II) acetate hydrate is an octapeptide analog of angiotensin II. Saralasin acetate hydrate is a competitive angiotensin II receptor antagonist with a Ki value of 0.32 nM for 74% of the binding sites, and has partial agonist activity as well. Saralasin acetate hydrate can be used for the research of renovascular hypertension, renin-dependent (angiotensinogenic) hypertension. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. P Schelling, et al. Effects of angiotensin II and angiotensin II antagonist saralasin on cell growth and renin in 3T3 and SV3T3 cells. J Cell Physiol. 1979 Mar;98(3):503-13. [Content Brief]
- [3]. Maziar Mohammad Akhavan, et al. A non-radioactive method for angiotensin II receptor binding studies using the rat liver. J Pharmacol Toxicol Methods. 2006 May-Jun;53(3):206-14. [Content Brief]
- [6]. Campbell WB, et al. Saralasin-induced renin release: its blockade by prostaglandin synthesis inhibitors in the conscious rat. Hypertension. 1979;1(6):637‐642. [Content Brief]
Keywords